TO:

FR:
DT:
RE:

Campaign for Sustainable Rx Pricing (CSRxP)
Morning Consult
November 18, 2015
Poll Results in Iowa, Nevada, New Hampshire and South Carolina

Morning Consult conducted four surveys on behalf of the Campaign for Sustainable
Rx Pricing in key presidential nominating states -- Iowa, Nevada, New Hampshire,
and South Carolina on the subject of presidential politics, health care and
prescription drug pricing from November 6-16, 2015.

Morning Consult interviewed nearly 2,500 registered voters overall, including 627
registered voters in Iowa, 641 registered voters in Nevada, 530 registered voters in
New Hampshire, and 627 registered voters in South Carolina. The surveys were
conducted using a mixed methodology of online and phone interviews and results
from the state surveys have a margin of error of 4 to 5 percentage points.

Trump and Clinton lead fields in all four states
Donald Trump leads the Republican field across the four states and his level of
support among registered voters who say they are likely to vote in the Republican
caucus or primary approaches or exceeds 30 percent. Ben Carson places second
across the board and Marco Rubio is third among Republican voters in all four
states.

Table 1: Vote Choice for top Republican Candidates
Candidate
Iowa
Nevada
New
South Carolina
Hampshire
Donald Trump
29
38
33
27
Ben Carson
17
18
15
25
Marco Rubio
12
12
9
10
Ted Cruz
9
7
9
10
Jeb Bush
9
6
5
10

Hillary Clinton holds a more than three-to-one lead (64-to-20) over Bernie Sanders
among registered voters who say they are likely to vote in the Democratic primary
in South Carolina, but Clinton and Sanders are virtually tied among primary voters
in New Hampshire (48-to-44).

Table 2: Vote Choice for top Democratic Candidates
Candidate
Iowa
Nevada
New
South Carolina
Hampshire
Hillary Clinton
55
59
48
64
Bernie Sanders
37
30
44
20
Martin
2
2
3
0
OMalley

Key head-to-head general election match-ups with Hillary Clinton and four
Republican candidates are close across the four states. Trump leads Clinton by three
points in Nevada, where Clinton leads Bush by six points in Nevada. Clinton edges
out all candidates in New Hampshire. In Iowa, Ben Carson holds a six point lead over
Clinton. Clinton trails all four candidates in South Carolina.

Table 3: General election match-ups with Hillary Clinton. Clinton number is first
Candidate
Iowa
Nevada
New
South Carolina
Hampshire
Jeb Bush
40-41
44-38
42-40
39-44
Ben Carson
40-46
44-41
43-41
37-48
Marco Rubio
40-43
42-42
42-40
38-46
Donald Trump
41-40
41-44
45-38
41-44

Policies to increase transparency in drug pricing receive broad support
Seven in 10 support requiring drug companies to publish research and
development, marketing and sales costs for their drugs (70% in IA; 71% in NV; 73%
in NH; 69% in SC) and nine in 10 say its a good idea to tell consumers how much
new prescription drugs cost in relation to existing drugs (88% in IA; 91% in NV;
88% in NH; 89% in SC).

Nine in 10 voters say it is important for presidential candidates to address issues
such as holding down rising prescription drug costs and making health care more
affordable for the middle class. Democrats are more likely than Republicans to say it
is very important for a candidate in the presidential race to address holding down
rising prescription drug costs.

Table 4: % Who Say Its Very Important For a Presidential Candidate to Address
Holding Down the Rising Costs of Prescription Drugs
Party
Iowa
Nevada
New
South Carolina
Hampshire
Democrats
72
66
56
74
Republicans
53
63
66
65
Independents
68
70
58
71

Voters concerned about prescription drug pricing
Three in 10 voters say prescription drug company profits are most responsible for
the higher price of prescription drugs (31% in IA; 34% in NV; 33% in NH; 30% in
SC). In all states, younger voters are more likely to cite prescription drug company
profits as the main driver of prescription drug costs, whereas voters 65 years of age
and older are most likely to say drug costs are driven by a combination of factors
drug company profits, drug advertising, research and development costs and
government regulation.

Eight in 10 voters overall, and about nine in 10 seniors say the price of some new
prescription drugs costing $100,000 or more for a year of treatment is unacceptable
and jeopardizes innovation in the American health care system. Fewer, about one in
10, say the price of some new prescription drugs costing $100,000 or more is
acceptable and what we have to pay for innovative, life-saving drug treatments.

Other Key Findings:
Eight in 10 voters say that drug companies need to price their products in a
way that the entire health care system can afford instead of charging as much
as possible to maximize returns for shareholders.
Seven in 10 voters believe that if prescription drug prices continue to
increase that the government should ensure that drug price increases are
limited.
Six in 10 voters who take prescription drugs say the price they pay for their
prescription has increased
Three in 10 Americans say they have not taken a prescription drug due to its
cost
Nearly seven in 10 voters support the FDA creating a faster review and
approval process for low cost prescription drugs

###